Stockscreener 앱 받기
33.86
1.45%
-0.56
Stoke Therapeutics Inc 주식(STOK)의 최신 뉴스
Stoke Therapeutics Hits Day Low at $33.50 Amid Price Pressure - Markets Mojo
Insider Sell: Adrian Krainer Sells 7,229 Shares of Stoke Therape - GuruFocus
Biogen (BIIB) Reports Promising Data on Zorevunersen for Dravet Syndrome - GuruFocus
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome - The AI Journal
Stoke Therapeutics and Biogen Announce Promising Results for Zorevunersen in Treating Dravet Syndrome, Supporting Phase 3 EMPEROR Study - Quiver Quantitative
Stoke Therapeutics (STOK) director sells 7,229 shares under 10b5-1 plan - Stock Titan
Stoke Therapeutics grants $697,125 bonus to CEO Ian F. Smith By Investing.com - Investing.com Australia
Stoke Therapeutics grants $697,125 bonus to CEO Ian F. Smith - Investing.com India
Stoke Therapeutics Awards Discretionary Bonus to CEO Smith - TipRanks
Stoke Therapeutics (NASDAQ: STOK) awards CEO Ian F. Smith $697,125 2025 bonus equivalent - Stock Titan
STOK: Phase 3 Dravet study nears full enrollment, with strong efficacy and broad market potential - TradingView
STOK Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
[144] Stoke Therapeutics, Inc. SEC Filing - Stock Titan
Stoke Therapeutics (NASDAQ:STOK) Sets New 1-Year HighWhat's Next? - MarketBeat
Stoke Therapeutics stock hits 52-week high at 38.8 USD By Investing.com - Investing.com Canada
Stoke Therapeutics stock hits 52-week high at 38.8 USD - Investing.com India
Portfolio Shifts: What dividend growth rate does Stoke Therapeutics Inc offerJuly 2025 Levels & Real-Time Market Sentiment Alerts - baoquankhu1.vn
(STOK) Movement as an Input in Quant Signal Sets - Stock Traders Daily
STOK PE Ratio & Valuation, Is STOK Overvalued - Intellectia AI
Stoke Therapeutics (STOK) Investor Outlook: A Promising Biotech with 17.3% Upside Potential - DirectorsTalk Interviews
Stoke Therapeutics Opens with 6.45% Gain, Outperforming S&P 500's 0.69% - Markets Mojo
Stoke Therapeutics (NASDAQ:STOK) Upgraded to Strong-Buy at Wolfe Research - MarketBeat
Risk Analysis: What is the earnings history of Stoke Therapeutics IncJuly 2025 Outlook & Weekly High Return Opportunities - baoquankhu1.vn
Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference - PharmiWeb.com
Stoke Therapeutics stock swings premarket after Wolfe starts coverage with $40 target (STOK) - TechStock²
Wolfe Research Initiates Coverage on Stoke Therapeutics (STOK) w - GuruFocus
Wolfe Research Initiates Coverage of Stoke Therapeutics (STOK) with Outperform Recommendation - Nasdaq
Forecasting The Future: 5 Analyst Projections For Stoke Therapeutics - Benzinga
A Look At Stoke Therapeutics (STOK) Valuation After Recent Share Price Momentum - Yahoo Finance
Stoke Therapeutics Shares Poised for Pivotal Clinical Updates - AD HOC NEWS
Is Stoke Therapeutics Inc. stock a good pick for beginnersJuly 2025 Big Picture & Real-Time Stock Entry Alerts - mfd.ru
What is the PEG ratio of Stoke Therapeutics Inc.July 2025 Earnings & AI Enhanced Trading Alerts - mfd.ru
Stoke Therapeutics, Inc. (STOK) Stock Analysis: Impressive Revenue Growth and Promising Upside - DirectorsTalk Interviews
Is Stoke Therapeutics Inc. in a long term uptrend2025 Price Momentum & Free Low Drawdown Momentum Trade Ideas - mfd.ru
STOK: Cantor Fitzgerald Analyst to Host Conference Call with Man - GuruFocus
Stoke Therapeutics (NASDAQ: STOK) awards options and RSUs to counsel - Stock Titan
Stoke Therapeutics (NASDAQ:STOK) Stock Price Up 10.2%Here's Why - MarketBeat
45,205 Shares in Stoke Therapeutics, Inc. $STOK Acquired by Principal Financial Group Inc. - MarketBeat
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Liquidity Mapping Around (STOK) Price Events - Stock Traders Daily
Growth Value: What are the analyst revisions for MESAIs Stoke Therapeutics Inc stock a good investment in YEARPortfolio Gains Report & AI Enhanced Trading Alerts - baoquankhu1.vn
Needham Maintains Stoke Therapeutics (STOK) Buy Recommendation - MSN
Stoke Therapeutics spotlights durable Dravet gains, Phase 3 timeline, and new ADOA program at summit - MarketBeat
Stoke Therapeutics, Inc. (STOK) Stock Analysis: Unveiling a 31% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Ideas Watch: What is the earnings history of Stoke Therapeutics IncQuarterly Trade Review & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
STOK: Four-year data show durable seizure reduction and cognitive gains, with phase 3 readout expected 2027 - TradingView
Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Mo - pharmiweb.com
Stoke Therapeutics announces first patient dosed in Phase 1 study of STK-002 - marketscreener.com
Is Stoke Therapeutics Inc. a cyclical or defensive stockQuarterly Earnings Report & Daily Technical Forecast Reports - mfd.ru
Stoke Therapeutics announced that the dose-escalation phase for the first four cohorts of its research project will continue into 2026 and early 2027. - Bitget
Stoke Therapeutics Announces First Patient Dosed In Phase 1 Study Of Stk-002 - TradingView
Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA) - Business Wire
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Quarterly Earnings: What is the PEG ratio of Stoke Therapeutics IncJuly 2025 Movers & Fast Gain Stock Trading Tips - baoquankhu1.vn
Guggenheim Upgrades Stoke Therapeutics (NASDAQ:STOK) to "Strong-Buy" - MarketBeat
Why (STOK) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Earnings Recap: How does Stoke Therapeutics Inc score in quality rankingsShare Buyback & Target Return Focused Stock Picks - baoquankhu1.vn
Penserra Capital Management LLC Acquires New Position in Stoke Therapeutics, Inc. $STOK - MarketBeat
3.97%
자본화:
|
볼륨(24시간):